Abstract
Twenty-six healthy males took part in this double-blind, randomised, placebo-controlled, two-period, cross-over study. Pantoprazole (40 mg) (test) or placebo (reference) were administered once daily, for 8 days, with a 3 week washout period. A single oral dose of 25 mg warfarin sodium was co-administered with pantoprazole or placebo on Day 2 of each treatment period. The 90% confidence intervals for the 'test/reference' mean ratios of the excess AUC(0.168 h) of prothrombin time and AUC(0.168 h) of factor VII, and of Cmax, AUC and t1/2 of both R- and S-warfarin fell within the equivalence range of 80% to 125%. These results suggest that pantoprazole does not alter the pharmacokinetics or pharmacodynamics of warfarin.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- De Mey C., Meineke I., Steinijans V. W., Huber R., Hartmann M., Bliesath H., Wurst W. Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction. Int J Clin Pharmacol Ther. 1994 Feb;32(2):98–106. [PubMed] [Google Scholar]
- Diletti E., Hauschke D., Steinijans V. W. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol. 1991 Jan;29(1):1–8. [PubMed] [Google Scholar]
- Endrenyi L., Fritsch S., Yan W. Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence. Int J Clin Pharmacol Ther Toxicol. 1991 Oct;29(10):394–399. [PubMed] [Google Scholar]
- Müller P., Simon B., Khalil H., Lühmann R., Leucht U., Schneider A. Dose-range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients. Z Gastroenterol. 1992 Nov;30(11):771–775. [PubMed] [Google Scholar]
- Sauter R., Steinijans V. W., Diletti E., Böhm A., Schulz H. U. Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1992 Jul;30(7):233–256. [PubMed] [Google Scholar]
- Schall R., Luus H. G. Comparison of absorption rates in bioequivalence studies of immediate release drug formulations. Int J Clin Pharmacol Ther Toxicol. 1992 May;30(5):153–159. [PubMed] [Google Scholar]
- Schulz H. U., Hartmann M., Steinijans V. W., Huber R., Lührmann B., Bliesath H., Wurst W. Lack of influence of pantoprazole on the disposition kinetics of theophylline in man. Int J Clin Pharmacol Ther Toxicol. 1991 Sep;29(9):369–375. [PubMed] [Google Scholar]
- Simon B., Müller P., Bliesath H., Lühmann R., Hartmann M., Huber R., Wurst W. Single intravenous administration of the H+, K(+)-ATPase inhibitor BY 1023/SK&F 96022--inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Aliment Pharmacol Ther. 1990 Jun;4(3):239–245. doi: 10.1111/j.1365-2036.1990.tb00468.x. [DOI] [PubMed] [Google Scholar]
- Simon B., Müller P., Hartmann M., Bliesath H., Lühmann R., Huber R., Bohnenkamp W., Wurst W. Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. Z Gastroenterol. 1990 Sep;28(9):443–447. [PubMed] [Google Scholar]
- Steinijans V. W., Hartmann M., Huber R., Radtke H. W. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol. 1991 Aug;29(8):323–328. [PubMed] [Google Scholar]
- Tucker G. T. The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther. 1994;8 (Suppl 1):33–38. doi: 10.1111/j.1365-2036.1994.tb00233.x. [DOI] [PubMed] [Google Scholar]